At a glance
Splisense is targeting the Root Cause of Genetic and Pulmonary Diseases. Positioned as a clinical stage company, Splisense is developing a transformative RNA-based treatments for unmet needs relating to diverse pulmonary diseases. The company’s technology is based on Antisense Oligonucleotides (ASOs) that restore and modify protein functionality, addressing untreatable genetic illnesses like Cystic Fibrosis and pulmonary diseases such as Idiopathic Pulmonary Fibrosis.
Investors
Integra Holdings, Orbimed. Israel Biotech Fund, Cystic Fibrosis, Foundation
MORE COMPANIES
